Publications by authors named "Marcin Jakubiec"

Claim this Profile
D
Discovery of novel hybrid pyrrolidin-2-one derivatives exhibiting potent antiseizure and antinociceptive effects in preclinical models.
Marcin Jakubiec, Michał Abram, Mirosław Zagaja, Katarzyna Socała, Vanja Panic

Biomed Pharmacother· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of SSR504734, a Selective Glycine Transporter Type 1 Inhibitor, on Seizure Thresholds, Neurotransmitter Levels, and Inflammatory Markers in Mice.
Nikola Gapińska, Piotr Wlaź, Elżbieta Wyska, Artur Świerczek, Krzysztof Kamiński, Marcin Jakubiec

ACS Chem Neurosci· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancement of Glutamate Uptake as Novel Antiseizure Approach: Preclinical Proof of Concept.
Krzysztof Kamiński, Katarzyna Socała, Michał Abram, Marcin Jakubiec, Katelyn L Reeb

Ann Neurol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of New 3-(Benzo[]Thiophen-2-yl)Pyrrolidine-2,5-Dione Derivatives as Potent Antiseizure and Antinociceptive Agents-In Vitro and In Vivo Evaluation.
Anna Rapacz, Marcin Jakubiec, Michał Abram, Jakub Jasiński, Karolina Chrzan

Pharmaceuticals (Basel)· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TRPV1 channel in the pathophysiology of epilepsy and its potential as a molecular target for the development of new antiseizure drug candidates.
Katarzyna Socała, Marcin Jakubiec, Michał Abram, Jakub Mlost, Katarzyna Starowicz

Prog Neurobiol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Profiling of New Multimodal Phenylglycinamide Derivatives as Potent Antiseizure and Antinociceptive Drug Candidates.
Marcin Jakubiec, Michał Abram, Mirosław Zagaja, Katarzyna Socała, Vanja Panic

ACS Chem Neurosci· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of Novel Alaninamide Derivatives with Anticonvulsant Activity and Favorable Safety Profiles in Animal Models.
Michał Abram, Marcin Jakubiec, Paulina Koczurkiewicz-Adamczyk, Agata Doroz-Płonka, Anna Rapacz

Int J Mol Sci· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Alaninamide Derivatives with Drug-like Potential for Development as Antiseizure and Antinociceptive Therapies─In Vitro and In Vivo Characterization.
Marcin Jakubiec, Michał Abram, Mirosław Zagaja, Marta Andres-Mach, Joanna Szala-Rycaj

ACS Chem Neurosci· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comprehensive assessment of palmatine as anticonvulsant agent - In vivo and in silico studies.
Dorota Nieoczym, Marta Marszalek-Grabska, Radoslaw Szalak, Uday Kundap, Agnieszka A Kaczor, Marcin Jakubiec

Biomed Pharmacother· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Vivo and In Vitro Characterization of Close Analogs of Compound KA-11, a New Antiseizure Drug Candidate.
Marta Andres-Mach, Mirosław Zagaja, Joanna Szala-Rycaj, Aleksandra Szewczyk, Michał Abram, Marcin Jakubiec

Int J Mol Sci· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of ()--Benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide [], a Novel Orally Bioavailable EAAT2 Modulator with Drug-like Properties and Potent Antiseizure Activity .
Michał Abram, Marcin Jakubiec, Katelyn Reeb, Mary Hongying Cheng, Robin Gedschold

J Med Chem· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New Phenylglycinamide Derivatives with Hybrid Structure as Candidates for New Broad-Spectrum Anticonvulsants.
Marcin Jakubiec, Michał Abram, Mirosław Zagaja, Marta Andres-Mach, Aleksandra Szewczyk

Cells· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of New Compounds with Anticonvulsant and Antinociceptive Properties in a Group of 3-substituted (2,5-dioxo-pyrrolidin-1-yl)(phenyl)-Acetamides.
Michał Abram, Marcin Jakubiec, Anna Rapacz, Szczepan Mogilski, Gniewomir Latacz

Int J Mol Sci· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis, anticonvulsant, and antinociceptive activity of new 3-(3-methyl-2,5-dioxo-3-phenylpyrrolidin-1-yl)propanamides and 3-phenyl-butanamides.
Jolanta Obniska, Małgorzata Góra, Anna Rapacz, Kinga Sałat, Sabina Rybka, Marcin Jakubiec

Arch Pharm (Weinheim)· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Search for New Anticonvulsants in a Group of (2,5-Dioxopyrrolidin-1-yl)(phenyl)Acetamides with Hybrid Structure-Synthesis and In Vivo/In Vitro Studies.
Michał Abram, Marcin Jakubiec, Anna Rapacz, Szczepan Mogilski, Gniewomir Latacz

Int J Mol Sci· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-Benzyl-(2,5-dioxopyrrolidin-1-yl)propanamide (AS-1) with Hybrid Structure as a Candidate for a Broad-Spectrum Antiepileptic Drug.
Krzysztof Kamiński, Katarzyna Socała, Mirosław Zagaja, Marta Andres-Mach, Michał Abram, Marcin Jakubiec

Neurotherapeutics· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chirality as an Important Factor for the Development of New Antiepileptic Drugs.
Michał Abram, Marcin Jakubiec, Krzysztof Kamiński

ChemMedChem· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis